By Vivienne Raper, PhD

Drugs based on mRNA have taken off since the development of mRNA-based COVID-19 vaccines. Jake Becraft, PhD, CEO and co-founder of Strand Therapeutics, spoke on a panel about DNA supply at SynBioBeta 2023. Here, GEN speaks with Becraft about the challenges of sourcing raw materials and developing a successful manufacturing process.

 

Jake Becraft, PhD

GEN: Have mRNA therapeutics become more popular recently?

Becraft: I’ve been a researcher in the mRNA space for a decade now, and since COVID-19 there’s been a lot more interest in this space. Multiple companies have [now] emerged to take mRNA to the next level.

 

GEN:  What drugs is your company working on?

Becraft: We’re still at preclinical stage, working toward starting a Phase I clinical trial on a first set of cancer patients within the next year. [Our pipeline includes treatments for several types] of solid tumors.

 

GEN: What’s the main challenge in sourcing DNA for mRNA therapy manufacturing?

Becraft: The challenge has always been to find reputable suppliers to produce DNA at large scales. Only a few groups make high-quality DNA, and it can be expensive to source as a lot of commercial DNA is still made by growing and purifying it from bacterial cells.

There are, however, some next-generation approaches [emerging] that are cleaner and [produce a] cleaner product, which can be scaled up without the use of bacterial DNA.

 

GEN: What are the challenges to mRNA manufacturing?

Becraft: Because we’re developing mRNA-based treatments for cancer and rare diseases, we need to build complicated strands of mRNA that are longer than [for] vaccines. They also need to be very pure and non-immunogenic.

[One of the challenges] is copying the DNA into RNA. You need to make sure the full-length mRNA is made. If the DNA isn’t fully copied, it won’t do anything when injected and the [drug] will have lower efficacy. You also don’t want to form weird structures, such as double-stranded mRNA, which can activate an immune response in cells.

We use a process called in vitro transcription [to manufacture mRNA]. Essentially, you take a DNA template and then you put it in a bioreactor-like vessel that also contains an enzyme, a polymerase. This copies DNA into the same sequence, but in RNA. Then, you go through a series of purification steps that remove the DNA and enzyme, so you just end up with pure RNA at the end.

Previous articleStrategies to Boost rAAV Productivity
Next articleMeeting mRNA Demand